Recombinant Anti-EGR2 antibody [EPR4004] (ab108399)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4004] to EGR2
- Suitable for: WB
- Reacts with: Human
Overview
-
Product name
Anti-EGR2 antibody [EPR4004]
See all EGR2 primary antibodies -
Description
Rabbit monoclonal [EPR4004] to EGR2 -
Host species
Rabbit -
Tested Applications & Species
Application Species WB Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- LnCaP, HepG2, MCF7, and SH SY5Y cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR4004 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108399 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
ChIP |
Rat
|
IP |
Human
|
WB |
Human
|
All applications |
Mouse
Rat
|
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
1/1000 - 1/10000. Predicted molecular weight: 53 kDa.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 53 kDa. |
Target
-
Function
Sequence-specific DNA-binding transcription factor. Binds to two specific DNA sites located in the promoter region of HOXA4. -
Involvement in disease
Defects in EGR2 are a cause of congenital hypomyelination neuropathy (CHN) [MIM:605253]. Inheritance can be autosomal dominant or recessive. Recessive CHN is also known as Charcot-Marie-Tooth disease type 4E (CMT4E). CHN is characterized clinically by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities.
Defects in EGR2 are a cause of Charcot-Marie-Tooth disease type 1D (CMT1D) [MIM:607678]. CMT1D is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.
Defects in EGR2 are a cause of Dejerine-Sottas syndrome (DSS) [MIM:145900]; also known as Dejerine-Sottas neuropathy (DSN) or hereditary motor and sensory neuropathy III (HMSN3). DSS is a severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. DSS is characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome. -
Sequence similarities
Belongs to the EGR C2H2-type zinc-finger protein family.
Contains 3 C2H2-type zinc fingers. -
Post-translational
modificationsUbiquitinated by WWP2 leading to proteasomal degradation. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 1959 Human
- Entrez Gene: 13654 Mouse
- Entrez Gene: 114090 Rat
- GenBank: BC035625 Human
- Omim: 129010 Human
- SwissProt: P11161 Human
- SwissProt: P08152 Mouse
- SwissProt: P51774 Rat
see all -
Alternative names
- AT591 antibody
- CMT1D antibody
- CMT4E antibody
see all
Images
-
All lanes : Anti-EGR2 antibody [EPR4004] (ab108399) at 1/1000 dilution
Lane 1 : LnCaP cell lysate
Lane 2 : HepG2 cell lysate
Lane 3 : MCF7 cell lysate
Lane 4 : SH SY5Y cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 53 kDa
References (11)
ab108399 has been referenced in 11 publications.
- Li Z et al. MicroRNA-124 Overexpression in Schwann Cells Promotes Schwann Cell-Astrocyte Integration and Inhibits Glial Scar Formation Ability. Front Cell Neurosci 14:144 (2020). PubMed: 32714149
- Liu F et al. Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells. Cancer Sci 109:65-73 (2018). WB . PubMed: 29059496
- Miyamoto Y et al. BIG1/Arfgef1 and Arf1 regulate the initiation of myelination by Schwann cells in mice. Sci Adv 4:eaar4471 (2018). PubMed: 29740613
- Niu RN et al. Overexpression of Egr2 and Egr4 protects rat brains against ischemic stroke by downregulating JNK signaling pathway. Biochimie 149:62-70 (2018). WB ; Rat . PubMed: 29580816
- Fan Y et al. MiR-377 Regulates Inflammation and Angiogenesis in Rats After Cerebral Ischemic Injury. J Cell Biochem 119:327-337 (2018). PubMed: 28569430